Vertex Pharmaceuticals Enters Material Definitive Agreement
Ticker: VRTX · Form: 8-K · Filed: Apr 11, 2024 · CIK: 875320
Sentiment: neutral
Topics: material-definitive-agreement, corporate-filing
TL;DR
Vertex Pharma inked a new deal, filing an 8-K on April 10th.
AI Summary
On April 10, 2024, Vertex Pharmaceuticals Incorporated entered into a Material Definitive Agreement. The filing also includes information on Other Events and Financial Statements and Exhibits. Vertex Pharmaceuticals is incorporated in Massachusetts and its principal executive offices are located in Boston.
Why It Matters
This filing indicates a significant new agreement for Vertex Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Numbers
- 000-19319 — Commission File Number (Identifies Vertex Pharmaceuticals' SEC filings)
- 04-3039129 — IRS Employer Identification No. (Tax identification number for Vertex Pharmaceuticals)
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- April 10, 2024 (date) — Date of earliest event reported
- Massachusetts (location) — State of incorporation
- Boston (location) — Address of principal executive offices
- 50 Northern Avenue (address) — Principal executive office address
FAQ
What type of Material Definitive Agreement did Vertex Pharmaceuticals enter into?
The filing states that Vertex Pharmaceuticals Incorporated entered into a Material Definitive Agreement on April 10, 2024, but the specific details of the agreement are not provided in the excerpt.
What is the Commission File Number for Vertex Pharmaceuticals?
The Commission File Number for Vertex Pharmaceuticals Incorporated is 000-19319.
Where are Vertex Pharmaceuticals' principal executive offices located?
Vertex Pharmaceuticals' principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts 02210.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 10, 2024.
What is Vertex Pharmaceuticals' fiscal year end?
Vertex Pharmaceuticals' fiscal year ends on December 31st.
Filing Stats: 3,049 words · 12 min read · ~10 pages · Grade level 14.7 · Accepted 2024-04-11 07:13:31
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq
- $0.001 — common stock of the Company, par value $0.001 per share (the " Shares "), at a price
- $65.00 — r share (the " Shares "), at a price of $65.00 per share (the " Offer Price "), net to
- $173 million — ired to pay Parent a termination fee of $173 million. A copy of the Merger Agreement is at
Filing Documents
- d752930d8k.htm (8-K) — 48KB
- 0001193125-24-092475.txt ( ) — 171KB
- vrtx-20240410.xsd (EX-101.SCH) — 3KB
- vrtx-20240410_lab.xml (EX-101.LAB) — 17KB
- vrtx-20240410_pre.xml (EX-101.PRE) — 11KB
- d752930d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits Exhibit No. Description 2.1* Agreement and Plan of Merger by and among Alpine Immune Sciences, Inc., Vertex Pharmaceuticals Incorporated and Adams Merger Sub, Inc., dated April 10, 2024 (incorporated herein by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by Alpine Immune Sciences, Inc. with the SEC on April 10, 2024). 10.1 Form of Tender and Support Agreement (incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Alpine Immune Sciences, Inc. with the SEC on April 10, 2024). 10.2 Form of Frazier Tender and Support Agreement (incorporated herein by reference to Exhibit 10.2 of the Current Report on Form 8-K filed by Alpine Immune Sciences, Inc. with the SEC on April 10, 2024). 99.1 Joint Press Release, dated April 10, 2024 (incorporated herein by reference to Exhibit 99.1 of the Current Report on Form 8-K filed by Alpine Immune Sciences, Inc. with the SEC on April 10, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: April 11, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer